TFPI-2 inhibitors are a class of chemical compounds that specifically target tissue factor pathway inhibitor-2 (TFPI-2), a protein involved in regulating extracellular proteolysis and maintaining extracellular matrix integrity. TFPI-2 is a member of the Kunitz-type serine protease inhibitor family, and it functions primarily by inhibiting a variety of proteases, including plasmin, trypsin, and matrix metalloproteinases (MMPs). By inhibiting these proteases, TFPI-2 plays a crucial role in controlling processes such as tissue remodeling, cell migration, and the degradation of the extracellular matrix. Inhibitors of TFPI-2 disrupt its normal regulatory function by preventing it from interacting with and inhibiting its target proteases, leading to an increase in proteolytic activity in the extracellular environment. This can result in significant changes in the behavior of cells and the surrounding tissue architecture due to the altered balance of protease activity.
The development of TFPI-2 inhibitors typically involves identifying molecules that can selectively bind to TFPI-2 and interfere with its inhibitory action on proteases. These inhibitors may function by binding to the Kunitz domains of TFPI-2, which are critical for its interaction with proteases, or by disrupting its overall conformation, thus hindering its ability to regulate proteolytic enzymes effectively. Structural studies of TFPI-2 have provided valuable insights into its functional domains, enabling the design of inhibitors that specifically target these regions without affecting other protease inhibitors. TFPI-2 inhibitors are important tools for studying the role of protease regulation in tissue dynamics and provide a means to explore the biochemical mechanisms underlying extracellular matrix maintenance and protease-mediated processes. These inhibitors offer insights into how TFPI-2 modulates extracellular proteolysis, contributing to a deeper understanding of its role in various biological processes involving cell migration, invasion, and tissue remodeling.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Aprotinin | 9087-70-1 | sc-3595 sc-3595A sc-3595B | 10 mg 100 mg 1 g | $110.00 $400.00 $1615.00 | 51 | |
Serine protease inhibitor that can inhibit plasmin, potentially affecting the function of TFPI-2. | ||||||
Tranexamic acid | 1197-18-8 | sc-204921 sc-204921A | 5 g 10 g | $28.00 $49.00 | 10 | |
Inhibits plasminogen activation, potentially influencing the function of TFPI-2. | ||||||
Argatroban | 74863-84-6 | sc-201310 sc-201310A | 10 mg 50 mg | $115.00 $460.00 | 13 | |
Direct thrombin inhibitor, could potentially affect TFPI-2 function. | ||||||
Dabigatran | 211914-51-1 | sc-481166 | 5 mg | $205.00 | 1 | |
Another direct thrombin inhibitor, could potentially affect TFPI-2 function. | ||||||
Warfarin | 81-81-2 | sc-205888 sc-205888A | 1 g 10 g | $72.00 $162.00 | 7 | |
Anticoagulant that inhibits vitamin K reductase, potentially affecting coagulation and TFPI-2 function. | ||||||
Heparin | 9005-49-6 | sc-507344 | 25 mg | $117.00 | 1 | |
Anticoagulant that enhances antithrombin III, potentially influencing the function of TFPI-2. | ||||||
Fondaparinux | 104993-28-4 | sc-507424 | 10 mg | $297.00 | ||
Factor Xa inhibitor, could potentially affect TFPI-2 function. | ||||||
Rivaroxaban | 366789-02-8 | sc-208311 | 2 mg | $155.00 | 18 | |
Another factor Xa inhibitor, could potentially affect TFPI-2 function. | ||||||